Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome

Singhal, Deepak
Kutyna, Monika M.
Chhetri, Rakchha
Wee, Li Yan A.
Hague, Sophia
Nath, Lakshmi
Nath, Shriram V.
Sinha, Romi
Wickham, Nicholas
Lewis, Ian D.
Ross, David M.
Bardy, Peter G.
To, Luen Bik
Reynolds, John
Wood, Erica M.
Roxby, David J.
Hiwase, Devendra K.

November 2017

Up to 90% of patients with a myelodysplastic syndrome require red blood cell transfusion; neverthele...

664 American Society of Hematology Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?

Heather A. Leitch
Linda M. Vickars

February 2015

The myelodysplastic syndromes (MDS) are characterized by cytopenias and risk of transformation to ac...

A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation *

Cremers, Eline M. P.
de Witte, Theo
de Wreede, Liesbeth
Eikema, Diderik-Jan
Koster, Linda
van Biezen, Anja
Finke, J. rgen
Socié, Gerard
Beelen, Dietrich
Maertens, Johan
Nagler, Arnon
Kobbe, Guido
Ziagkos, Dimitris
Itälä-Remes, Maija
Gedde-Dahl, Tobias
Sierra, Jorge
Niederwieser, Dietger
Ljungman, Per
Beguin, Yves
Ozkurt, Zubeyde Nur
Anagnostopoulos, Achilles
Jindra, Pavel
Robin, Marie
Kröger, Nicolaus

August 2019

Most myelodysplastic syndromes (MDS)-patients receive multiple red blood cell transfusions (RBCT). T...

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes.

de Swart L
Crouch S
Hoeks M
Smith A
Langemeijer S
Fenaux P
Symeonidis A
Cermâk J
Hellström-Lindberg E
Stauder R
Sanz G
Mittelman M
Holm MS
Malcovati L
Mądry K
Germing U
Tatic A
Savic A
Almeida AM
Gredelj-Simec N
Guerci-Bresler A
Beyne-Rauzy O
Culligan D
Kotsianidis I
Itzykson R
van Marrewijk C
Blijlevens N
Bowen D
de Witte T
EUMDS Registry Participants.

January 2020

Progression-free survival (PFS) of patients with lower-risk myelodysplastic syndromes (MDS) treated ...

Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients

Smith, Alexandra Gwen
Yu, Ge

June 2019

Progression-free survival of lower-risk myelodysplastic syndromes patients treated with red blood ce...

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes

Itzykson, Raphael
Crouch, S.
Travaglino, Erica
Smith, A.
Symeonidis, A.
Hellstrom-Lindberg, E.
Langemeijer, S.M.
Marrewijk, C.J. van
Witte, T.J. de
Fenaux, P.

January 2018

Contains fulltext : 195134.pdf (publisher's version ) (Open Access

Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial

Stanworth, SJ
Killick, S
McQuilten, ZK
Karakantza, M
Weinkove, R
Smethurst, H
Pankhurst, LA
Hodge, RL
Hopkins, V
Thomas, HL
Deary, AJ
Callum, J
Lin, Y
Wood, EM
Buckstein, R
Bowen, D
REDDS Investigators

January 2020

Optimal red cell transfusion support in myelodysplastic syndromes (MDS) has not been tested and esta...

Red Blood Cell Transfusion Dependence and Outcome after Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with de Novo Myelodysplastic Syndrome (MDS)

Platzbecker, Uwe
Bornhäuser, Martin
Germing, Ulrich
Stumpf, Julian
Scott, Bart L.
Kröger, Nicolaus
Schwerdtfeger, Rainer
Böhm, Alexandra
Kobbe, Guido
Theuser, Catrin
Rabitsch, Werner
Valent, Peter
Sorror, Mohamed L.
Ehninger, Gerhard
Deeg, H. Joachim

November 2008

The prognosis of patients with de novo myelodysplastic syndrome (MDS) who are red blood cell transfu...

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes

Swart, L. de
Reiniers, Chloe
Bagguley, Timothy
Marrewijk, C.J. van
Bowen, D.
Hellstrom-Lindberg, E.
Blijlevens, N.M.
Langemeijer, S.M.C.
Droste, J.A.H.
Swinkels, D.W.
Smith, A.
Witte, T.J.M. de

January 2018

Contains fulltext : 183944.pdf (publisher's version ) (Open Access

Association Between Transfusion Status and Overall Survival in Patients With Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis

Harnan, S.
Ren, S.
Gomersall, T.
Everson-Hock, E.S.
Sutton, A.
Dhanasiri, S.
Kulasekararaj, A.

April 2016

Introduction: Multiple studies show transfusion independence (TI) in myelodysplastic syndrome (MDS) ...

Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization

Evers, D.
Zwaginga, J.J.
Tijmensen, J.
Middelburg, R.A.
Haas, M. de
Vooght, K.M. De
Kerkhof, D. van de
Visser, O
Pequeriaux, N.C.V.
Hudig, F.
Bom, J.G. Van Der

January 2017

Contains fulltext : 169863.pdf (publisher's version ) (Open Access)Red cell alloim...

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome

Garelius, H.K.
Johnston, W.T.
Smith, A.G.
Park, S.
Swart, L. de
Fenaux, P.
Symeonidis, A.
Sanz, G.
Cermak, J.
Stauder, R.
Malcovati, L.
Mittelman, M.
Loosdrecht, A.A. van de
Marrewijk, C.J. van
Bowen, D.
Crouch, S.
Witte, T.J.M. de
Hellstrom-Lindberg, E.

January 2017

Item does not contain fulltextBACKGROUND: The EUMDS registry is an unique prospective, longitudinal ...

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective

de Witte T.
Malcovati L.
Fenaux P.
Bowen D.
Symeonidis A.
Mittelman M.
Stauder R.
Sanz G.
Cermak J.
Langemeijer S.
Hellstrom-Lindberg E.
Germing U.
Holm M. S.
Madry K.
Tatic A.
Almeida A. M.
Savic A.
Rogulj I. M.
Itzykson R.
Hoeks M.
Garelius H. G.
Culligan D.
Kotsianidis I.
Ades L.
van de Loosdrecht A. A.
van Marrewijk C.
Yu G.
Crouch S.
Smith A.

January 2020

Available evidence suggests that in most patients with LR-MDS the risk of death is not related to di...

Hospital Huddinge, Stockholm

Therese Ljung
Eva Hellström-lindberg

March 2015

Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoi...

Transfusion, Iron, and Leukemogenesis: Implications for Myelodysplastic Syndrome

Alan Chan, Lap Shu

November 2015

Patients with myelodysplastic syndrome (MDS) require chronic red blood cell (RBC) transfusion due to...

Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome

Singhal, Deepak
Kutyna, Monika M.
Chhetri, Rakchha
Wee, Li Yan A.
Hague, Sophia
Nath, Lakshmi
Nath, Shriram V.
Sinha, Romi
Wickham, Nicholas
Lewis, Ian D.
Ross, David M.
Bardy, Peter G.
To, Luen Bik
Reynolds, John
Wood, Erica M.
Roxby, David J.
Hiwase, Devendra K.

November 2017

Up to 90% of patients with a myelodysplastic syndrome require red blood cell transfusion; neverthele...

664 American Society of Hematology Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?

Heather A. Leitch
Linda M. Vickars

February 2015

The myelodysplastic syndromes (MDS) are characterized by cytopenias and risk of transformation to ac...

A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation *

Cremers, Eline M. P.
de Witte, Theo
de Wreede, Liesbeth
Eikema, Diderik-Jan
Koster, Linda
van Biezen, Anja
Finke, J. rgen
Socié, Gerard
Beelen, Dietrich
Maertens, Johan
Nagler, Arnon
Kobbe, Guido
Ziagkos, Dimitris
Itälä-Remes, Maija
Gedde-Dahl, Tobias
Sierra, Jorge
Niederwieser, Dietger
Ljungman, Per
Beguin, Yves
Ozkurt, Zubeyde Nur
Anagnostopoulos, Achilles
Jindra, Pavel
Robin, Marie
Kröger, Nicolaus

August 2019

Most myelodysplastic syndromes (MDS)-patients receive multiple red blood cell transfusions (RBCT). T...

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes.

de Swart L
Crouch S
Hoeks M
Smith A
Langemeijer S
Fenaux P
Symeonidis A
Cermâk J
Hellström-Lindberg E
Stauder R
Sanz G
Mittelman M
Holm MS
Malcovati L
Mądry K
Germing U
Tatic A
Savic A
Almeida AM
Gredelj-Simec N
Guerci-Bresler A
Beyne-Rauzy O
Culligan D
Kotsianidis I
Itzykson R
van Marrewijk C
Blijlevens N
Bowen D
de Witte T
EUMDS Registry Participants.

January 2020

Progression-free survival (PFS) of patients with lower-risk myelodysplastic syndromes (MDS) treated ...

Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients

Smith, Alexandra Gwen
Yu, Ge

June 2019

Progression-free survival of lower-risk myelodysplastic syndromes patients treated with red blood ce...

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes

Itzykson, Raphael
Crouch, S.
Travaglino, Erica
Smith, A.
Symeonidis, A.
Hellstrom-Lindberg, E.
Langemeijer, S.M.
Marrewijk, C.J. van
Witte, T.J. de
Fenaux, P.

January 2018

Contains fulltext : 195134.pdf (publisher's version ) (Open Access

Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial

Stanworth, SJ
Killick, S
McQuilten, ZK
Karakantza, M
Weinkove, R
Smethurst, H
Pankhurst, LA
Hodge, RL
Hopkins, V
Thomas, HL
Deary, AJ
Callum, J
Lin, Y
Wood, EM
Buckstein, R
Bowen, D
REDDS Investigators

January 2020

Optimal red cell transfusion support in myelodysplastic syndromes (MDS) has not been tested and esta...

Red Blood Cell Transfusion Dependence and Outcome after Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with de Novo Myelodysplastic Syndrome (MDS)

Platzbecker, Uwe
Bornhäuser, Martin
Germing, Ulrich
Stumpf, Julian
Scott, Bart L.
Kröger, Nicolaus
Schwerdtfeger, Rainer
Böhm, Alexandra
Kobbe, Guido
Theuser, Catrin
Rabitsch, Werner
Valent, Peter
Sorror, Mohamed L.
Ehninger, Gerhard
Deeg, H. Joachim

November 2008

The prognosis of patients with de novo myelodysplastic syndrome (MDS) who are red blood cell transfu...

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes

Swart, L. de
Reiniers, Chloe
Bagguley, Timothy
Marrewijk, C.J. van
Bowen, D.
Hellstrom-Lindberg, E.
Blijlevens, N.M.
Langemeijer, S.M.C.
Droste, J.A.H.
Swinkels, D.W.
Smith, A.
Witte, T.J.M. de

January 2018

Contains fulltext : 183944.pdf (publisher's version ) (Open Access

Association Between Transfusion Status and Overall Survival in Patients With Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis

Harnan, S.
Ren, S.
Gomersall, T.
Everson-Hock, E.S.
Sutton, A.
Dhanasiri, S.
Kulasekararaj, A.

April 2016

Introduction: Multiple studies show transfusion independence (TI) in myelodysplastic syndrome (MDS) ...

Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization

Evers, D.
Zwaginga, J.J.
Tijmensen, J.
Middelburg, R.A.
Haas, M. de
Vooght, K.M. De
Kerkhof, D. van de
Visser, O
Pequeriaux, N.C.V.
Hudig, F.
Bom, J.G. Van Der

January 2017

Contains fulltext : 169863.pdf (publisher's version ) (Open Access)Red cell alloim...

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome

Garelius, H.K.
Johnston, W.T.
Smith, A.G.
Park, S.
Swart, L. de
Fenaux, P.
Symeonidis, A.
Sanz, G.
Cermak, J.
Stauder, R.
Malcovati, L.
Mittelman, M.
Loosdrecht, A.A. van de
Marrewijk, C.J. van
Bowen, D.
Crouch, S.
Witte, T.J.M. de
Hellstrom-Lindberg, E.

January 2017

Item does not contain fulltextBACKGROUND: The EUMDS registry is an unique prospective, longitudinal ...

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective

de Witte T.
Malcovati L.
Fenaux P.
Bowen D.
Symeonidis A.
Mittelman M.
Stauder R.
Sanz G.
Cermak J.
Langemeijer S.
Hellstrom-Lindberg E.
Germing U.
Holm M. S.
Madry K.
Tatic A.
Almeida A. M.
Savic A.
Rogulj I. M.
Itzykson R.
Hoeks M.
Garelius H. G.
Culligan D.
Kotsianidis I.
Ades L.
van de Loosdrecht A. A.
van Marrewijk C.
Yu G.
Crouch S.
Smith A.

January 2020

Available evidence suggests that in most patients with LR-MDS the risk of death is not related to di...

Hospital Huddinge, Stockholm

Therese Ljung
Eva Hellström-lindberg

March 2015

Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoi...

Transfusion, Iron, and Leukemogenesis: Implications for Myelodysplastic Syndrome

Alan Chan, Lap Shu

November 2015

Patients with myelodysplastic syndrome (MDS) require chronic red blood cell (RBC) transfusion due to...

Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome

Singhal, Deepak
Kutyna, Monika M.
Chhetri, Rakchha
Wee, Li Yan A.
Hague, Sophia
Nath, Lakshmi
Nath, Shriram V.
Sinha, Romi
Wickham, Nicholas
Lewis, Ian D.
Ross, David M.
Bardy, Peter G.
To, Luen Bik
Reynolds, John
Wood, Erica M.
Roxby, David J.
Hiwase, Devendra K.

November 2017

Up to 90% of patients with a myelodysplastic syndrome require red blood cell transfusion; neverthele...

664 American Society of Hematology Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?

Heather A. Leitch
Linda M. Vickars

February 2015

The myelodysplastic syndromes (MDS) are characterized by cytopenias and risk of transformation to ac...

A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation *

Cremers, Eline M. P.
de Witte, Theo
de Wreede, Liesbeth
Eikema, Diderik-Jan
Koster, Linda
van Biezen, Anja
Finke, J. rgen
Socié, Gerard
Beelen, Dietrich
Maertens, Johan
Nagler, Arnon
Kobbe, Guido
Ziagkos, Dimitris
Itälä-Remes, Maija
Gedde-Dahl, Tobias
Sierra, Jorge
Niederwieser, Dietger
Ljungman, Per
Beguin, Yves
Ozkurt, Zubeyde Nur
Anagnostopoulos, Achilles
Jindra, Pavel
Robin, Marie
Kröger, Nicolaus

August 2019

Most myelodysplastic syndromes (MDS)-patients receive multiple red blood cell transfusions (RBCT). T...

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

Abstract

Extracted data

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

Abstract

Extracted data

Related items

Related items